LivaNova Plc (LIVN)

LivaNova reported strong Q4 and full-year 2025 results, exceeding analyst expectations, with revenue increases, but the stock declined pre-market on the announcement day. CMS increased provider reimbursement for VNS Therapy for Drug-Resistant Epilepsy procedures, expected to improve hospital economics. The FDA approved the aura6000 System for obstructive sleep apnea in adults who cannot tolerate PAP therapy, considered a key growth catalyst. Lucile Blaise was appointed as Global Head of Commercialization for Obstructive Sleep Apnea. The company recorded a U.S. GAAP diluted loss per share due to a SNIA environmental liability expense.

Based on historical stock performance data over 11 years, LivaNova PLC (LIVN) stock has shown some seasonal tendencies. Historically, November has been the strongest month for the stock, with an average return of 3.42% and a 64% win rate. Conversely, March has tended to be the weakest month, with an average return of -5.70%.

LivaNova Plc is a global medical technology company focused on developing and delivering therapeutic solutions for neurological and cardiac conditions, operating primarily within the medical devices sector. The company's business is centered on innovative medical technologies that aim to improve patient quality of life, safety, and access while reducing complications and healthcare costs. Its main business segments are Cardiopulmonary, providing products such as heart-lung machines and oxygenators, and Neuromodulation, focusing on devices like the VNS Therapy System for treating drug-resistant epilepsy and difficult-to-treat depression.

Headquartered in London, UK, LivaNova maintains a significant global presence, operating in more than 100 countries worldwide. The company's operational headquarters are split between Europe and the US. The United States accounts for 53% of proforma revenues, Europe for 20%, and the Rest of World for 27%.

LivaNova emphasizes a commitment to high quality and integrity in its operations, driven by a mission to improve patients' lives. No specific events significantly impacting LivaNova's brand reputation (either positively or negatively) in the past year (April 2025 - April 2026) were prominently reported in the search results. A past challenge related to bacterial contamination in certain 3T Heater-Cooler devices was noted in 2016.

LivaNova Plc has a highly institutionalized ownership structure, with over 95% of shares held by professional investors as of Q1 2025. Major institutional owners include BlackRock, Inc., Primecap Management Co/ca/, Millennium Management Llc, Vanguard Group Inc, Artisan Partners Limited Partnership, Aqr Capital Management Llc, Wellington Management Group Llp, State Street Corp, Dimensional Fund Advisors Lp, and Geode Capital Management, Llc. Individual investor ownership is approximately 18.61%, while insiders own about 0.28% of the company's stock.